| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10217769 | HPB | 2018 | 7 Pages |
Abstract
Use of pasireotide after pancreatic resection does not decrease CR-POPF, nor is it associated with reduced length of stay or postoperative complications. A multi-center randomized trial is warranted to study its true effect on outcomes after pancreatectomy.
Related Topics
Health Sciences
Medicine and Dentistry
Endocrinology, Diabetes and Metabolism
Authors
Stephanie Young, Michael L. Sung, Jennifer A. Lee, Louis A. DiFronzo, Victoria V. O'Connor,